TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs 2-iminobiotin (Primary)
- Indications Asphyxia
- Focus Adverse reactions
- Acronyms TIBOHCA
- 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 26 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 21 Jul 2016 New trial record